Bookmark and Share

CEO Stephen P. MacMillan, Hologic Inc Insider Buys $4.133M of Shares on February, 07, 2014

Stephen P. MacMillan, CEO & President of Hologic Inc., purchased 198,900 shares of Hologic (Stock Symbol: HOLX) at $20.78 per share for a total amount of $4.133 million on February, 07, 2014.

Hologic is based in Bedford, MA.

On 02/10/2014, three new peer-reviewed publications further validated the benefits of Hologic 3D mammography (tomosynthesis) in breast cancer screening.

On 02/03/2014, Hologic announced its latest quarterly results. Revenues of $612.4 million. Non-GAAP net income of $94.1 million, or $0.34 per diluted share, and adjusted EBITDA (non-GAAP earnings before interest, taxes, depreciation and amortization) of $213.5 million. Net loss of $5.4 million, or $0.02 per diluted share, calculated in accordance with U.S. generally accepted accounting principles (GAAP). Stephen P. MacMillan named President and Chief Executive Officer, and a member of the Board of Directors. FDA approval of the Aptima HPV 16 18/45 genotype assay for use on the Panther system. Voluntary prepayment of an additional $100 million on the Term Loan B facility on October 31, 2013. Redeemed in full $405 million of principal of the 2.00% Convertible Senior Notes issued in 2007. The following non-GAAP financial measures are included in this press release: revenues, net income, earnings per diluted share (EPS), and adjusted EBITDA.

According to Capital IQ, Hologic, Inc. has a market cap of $5.8 billion, an enterprise value of $9.57 billion, and trailing 12 month revenues of $2.46 billion.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. The company’s Breast Health segment offers full field digital mammography, C-view, screen-film mammography, computer aided detection, Trident specimen radiography, and stereotactic breast biopsy systems; healthcome mammography, breast biopsy, and breast brachytherapy products; and breast tomosynthesis, Selenia full field digital mammography platform, SecurView workstation, MammoPad breast cushions, photoconductor coatings, and Sentinelle medical magnetic resonance imaging breast coils and workstations. Its Diagnostics segment provides APTIMA family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, instrumentation, Invader chemistry platform, Cervista HPV tests, ThinPrep system, fetal fibronectin tests, Procleix family of assays, and infectious disease and virology products. The company’s GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; and Aquilex Fluid Control System to measure the inflow and outflow of fluid from the patient during hysteroscopic procedures. Its Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities. Hologic, Inc. sells its products through direct sales and service forces, and a network of independent distributors and sales representatives primarily in the United States, Europe, and the Asia-Pacific. The company has a strategic alliance with Quest Diagnostics Incorporated. Hologic, Inc. was founded in 1985 and is headquartered in Bedford, Massachusetts.

Stephen MacMillan’s most recent annual compensation from Hologic is a salary of [Enter $XXX,XXX], [Enter $XXX,XXXX] in other compensation, and a total compensation of [Enter $XX,XXXX]. Mr. MacMillan is 50 years old.

According to his biography, Mr. Stephen P. MacMillan is President, Chief Executive Officer, Director of the company. Mr. MacMillan was appointed as President, Chief Executive Officer and a director in December 2013. Prior to joining the Company, Mr. MacMillan served as the Chief Executive Officer of sBioMed, LLC, a biomedical research firm that produces infection control products, which he joined in October 2012. Prior to joining sBioMed, LLC, Mr. MacMillan served in various roles at Stryker Corporation, including as its Chief Operating Officer from June 2003 to December 2004, its President from June 2003 to February 2012, its Chief Executive Officer from January 2005 to February 2012 and its Chairman from January 2010 to February 2012. Mr. MacMillan began his career with Procter & Gamble in 1985 and later spent 11 years with Johnson & Johnson, where he served in various roles, including President of Johnson & Johnson’s consumer pharmaceuticals joint venture with Merck from December 1998 to December 1999. From March 2000 to March 2003, Mr. MacMillan served as Sector Vice President, Global Specialty Operations of Pharmacia Corporation, a global pharmaceutical company. Mr. MacMillan currently serves on the board of directors of Alere, Inc. Mr. MacMillan previously served on the board of directors of Texas Instruments Incorporated from 2008 to 2012. Mr. MacMillan holds a Bachelor of Arts degree in economics from Davidson College and is a graduate of the Harvard Business School’s Advanced Management Program. As our President and Chief Executive Officer, Mr. MacMillan has direct responsibility for the Company’s strategy and operations. This position, together with his many years of experience in the healthcare industry, make him an invaluable contributor to the Board.

All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .

About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.


Leave a Reply

  

  

  

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>


-------------------------------------------------------------------------------------------------------------------------
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com . About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.